Search
2024
2023
-
Sep 04, 2024
YolTech Receives U.S. FDA RPDD for YOLT-203 in Treating PH1Read More
-
Aug 27, 2024
YolTech Announces Licensing Agreement with Salubris for the Development and Commercialization of YOLT-101 in Mainland ChinaRead More
-
Aug 22, 2024
YolTech Therapeutics Administers First Patient Dose in IIT of YOLT-203, the World's First In Vivo Gene Editing Therapy for PH1Read More
-
Jul 11, 2024
First Patient Dosed in Phase I Clinical Trial of YOLT-201Read More
-
Jun 27, 2024
YolTech and Wimi Bio Form Licensing Partnership to Advance Gene Editing Technology in AgricultureRead More
